Epilepsy medication may be delivered via tiny device

Delivering medication right to the source of pain or illness without effecting the surrounding organs and tissues is almost impossible to achieve. Researcher at Linköping University have developed a device that solves that problem for epileptic patients.

The device is capable of both detecting the signal of an epileptic attack and deliver medication directly to an area the size of 20 square microns. While current medications are available to treat epilepsy, they often affect the organs and tissues in the body. A team of developers led by Daniel Simon set out to correct this problem through technology. The device includes sensor that detects nerve signals and a tiny ion pump that delivers the neurotransmitter GABA, a substance that inhibits stimuli in the central nervous system.

"Our technology makes it possible to interact with both healthy and sick neurons. We can now start investigating opportunities for finding therapies for neurological illnesses that arise so rapidly and so locally that the patient doesn't notice them," said Simon.

In a study, done on slices of brains in mice, the device’s sensor picks up the nerve signals and the correct dose of medication avoids affecting the surrounding body parts.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.